Evidence map›Paper›PMID 19785645›Full record

ReviewBritish journal of pharmacology2009

Impact of OATP transporters on pharmacokinetics.

A Kalliokoski, M Niemi

2 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 374 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
374citing papers in PubMed, 6 pooled it
25.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02448589 phase1terminatednot on this mapstarted 2014, after this paper: background citation

A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors

TypeinterventionalSponsorTaiho Oncology, Inc.Ran2014 to 2019Enrolled74ConditionsAdvanced Solid TumorsArmsTAS-119
NCT07541807 completednot on this mapstarted 2024, after this paper: background citation

Quantifying the Perturbation of Gadoxetate Kinetics by Metformin and Ciclosporin With Functional Magnetic Resonance Imaging of the Liver

TypeobservationalSponsorSheffield Teaching Hospitals NHS Foundation TrustRan2024 to 2025Enrolled12ConditionsLiver Dysfunction
3 · Its place in the literature

Who cites it

374 citing papers in PubMed, 6 syntheses or guidelines pooled it, 976 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Effects ofPharmacogenomics · 2019
    Trial
  15. Trial
  16. Article
  17. Article
  18. Impact of SLCO1B1 Gene Polymorphisms on Vadadustat Pharmacokinetics.European journal of drug metabolism and pharmacokinetics · 2026
    Observational
  19. Review
  20. Article

314 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

A KalliokoskiDepartment of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.
M Niemi
Helsinki University Hospital · FIUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Membrane transporters are now recognized as important determinants of the transmembrane passage of drugs. Organic anion transporting polypeptides (OATP) form a family of influx transporters expressed in various tissues important for pharmacokinetics. Of the 11 human OATP transporters, OATP1B1, OATP1B3 and OATP2B1 are expressed on the sinusoidal membrane of hepatocytes and can facilitate the liver uptake of their substrate drugs. OATP1A2 is expressed on the luminal membrane of small intestinal enterocytes and at the blood-brain barrier, potentially mediating drug transport at these sites. Several clinically used drugs have been identified as substrates of OATP transporters (e.g. many statins are substrates of OATP1B1). Some drugs may inhibit OATP transporters (e.g. cyclosporine) causing pharmacokinetic drug-drug interactions. Moreover, genetic variability in genes encoding OATP transporters can result in marked inter-individual differences in pharmacokinetics. For example, a single nucleotide polymorphism (c.521T > C, p.Val174Ala) in the SLCO1B1 gene encoding OATP1B1 decreases the ability of OATP1B1 to transport active simvastatin acid from portal circulation into the liver, resulting in markedly increased plasma concentrations of simvastatin acid and an enhanced risk of simvastatin-induced myopathy. SLCO1B1 polymorphism also affects the pharmacokinetics of many other, but not all (fluvastatin), statins and that of the antidiabetic drug repaglinide, the antihistamine fexofenadine and the endothelin A receptor antagonist atrasentan. This review compiles the current knowledge about the expression and function of human OATP transporters, their substrate and inhibitor specificities, as well as pharmacogenetics.

Indexed as

PharmacokineticsBlood-Brain BarrierDrug InteractionsGenetic VariationHumansIntestinal AbsorptionLiverLiver-Specific Organic Anion Transporter 1Organic Anion TransportersOrganic Anion Transporters, Sodium-IndependentPeptidesPharmaceutical PreparationsPharmacogeneticsSolute Carrier Organic Anion Transporter Family Member 1B3Liver-Specific Organic Anion Transporter 1Organic Anion TransportersOrganic Anion Transporters, Sodium-IndependentPeptidesPharmaceutical PreparationsSLCO1A2 protein, humanSLCO1B1 protein, humanSLCO1B3 protein, humanSLCO2B1 protein, humanSolute Carrier Organic Anion Transporter Family Member 1B3

Identifiers

PMID19785645
PMCPMC2765590
OpenAlexW1783939843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.